Regulatory News Roundup: Two Customs Strikes Against MyNicNaxs, U.K. Ad Enforcement
This article was originally published in The Tan Sheet
Executive Summary
Two Customs strikes against MyNicNaxs; drug claims and GMP problems; curcumin bioavailability claim nixed; and U.K. ad enforcement news.
You may also be interested in...
NDI Notification Estimate Unchanged: Health And Wellness Industry News
Biotek gets FDA's own-labeler lesson; MyNicNaxs shut down after ignoring warning; and FDA sticks with NDI notification cost estimate.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.